SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|
| K-cit | 5 mEq | Prolonged-release tablet · Oral use | 100 Bottle | SAR 147.35 | Generic · Prescription | Saudi Amarox | Valid |
| K-cit | 10 mEq | Prolonged-release tablet · Oral use | 100 Bottle | SAR 294.70 | Generic · Prescription | Saudi Amarox | Valid |
| Zyutra | 5 mEq | Tablet · Oral use | 100 Bottle | SAR 51.70 | Generic · Prescription | Qomel Co | Valid |
| Zyutra | 10 mEq | Extended-release tablet · Oral use | 100 Bottle | SAR 103.45 | Generic · Prescription | Qomel Co | Valid |
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|
| UROCIT-K | 5MEQ; 10MEQ; 15MEQ | tablet, extended release · oral | MISSION PHARMA | Prescription | 30 Aug 1985 |
| POTASSIUM CITRATE | 5MEQ; 10MEQ | tablet, extended release · oral | RISING | Prescription | 8 Jun 2006 |
| POTASSIUM CITRATE | 5MEQ; 10MEQ; 15MEQ | tablet, extended release · oral | ZYDUS PHARMS | Prescription | 6 Aug 2014 |
| POTASSIUM CITRATE | 5MEQ; 10MEQ; 15MEQ | tablet, extended release · oral | STRIDES PHARMA | Prescription | 11 Sep 2017 |
| POTASSIUM CITRATE | 5MEQ; 10MEQ; 15MEQ | tablet, extended release · oral | TEVA PHARMS USA INC | Prescription | 5 Mar 2018 |
| POTASSIUM CITRATE | 10MEQ; 15MEQ | tablet, extended release · oral | ANI PHARMS | Prescription | 14 Jan 2020 |
| POTASSIUM CITRATE | 10MEQ; 15MEQ | tablet, extended release · oral | BIONPHARMA | Prescription | 29 Jun 2020 |
| POTASSIUM CITRATE | 5MEQ; 10MEQ; 15MEQ | tablet, extended release · oral | ASCENT PHARMS INC | Prescription | 5 Feb 2021 |
| POTASSIUM CITRATE | 5MEQ; 10MEQ; 15MEQ | tablet, extended release · oral | ADAPTIS | Prescription | 19 Feb 2021 |
| POTASSIUM CITRATE | 20MEQ/PACKET **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**; 10MEQ/PACKET **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | for solution · oral | UT SW MEDCTR | Discontinued | 13 Oct 1988 |
| POTASSIUM CITRATE | 5MEQ; 10MEQ; 15MEQ | tablet, extended release · oral | TORRENT | Discontinued | 6 Feb 2024 |
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|
| UROCIT-K | 02353997 | 1080 MG | TABLET (EXTENDED-RELEASE) · ORAL | MISSION PHARMACAL COMPANY |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|
| US NADAC | POTASSIUM CITRATE ER 10 MEQ TB | $0.17516 | per EA | 23 Sep 2026 |
| US NADAC | POTASSIUM CITRATE ER 15 MEQ TB | $0.17423 | per EA | 23 Sep 2026 |
| US NADAC | POTASSIUM CITRATE ER 5 MEQ TAB | $0.12346 | per EA | 23 Sep 2026 |
| NHS Drug Tariff | Potassium citrate 3g granules for oral solution sachets sugar free | £5.25 | 6 sachet | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Combinations containing Potassium citrate
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.